Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Mar 31, 2016 in Diabetes mellitus | 0 comments

In a nutshell

This study examined whether blood pressure is adequately controlled in patients with type 2 diabetes who are at high risk of cardiovascular disease. The authors concluded that blood pressure is not sufficiently controlled in the majority of patients with type 2 diabetes.

Some background

Cardiovascular disease (CVD) is a common complication in patients with type 2 diabetes. CVD is the narrowing or blockage of blood vessels and can lead to heart failure or stroke. Controlling blood pressure is an important part of CVD prevention. Blood pressure in T2D patients should ideally be less than 130/80 mmHg. However, it can be difficult to achieve this target, even with multiple blood-pressure lowering drugs.

Methods & findings

This study aimed to determine whether blood pressure is adequately controlled in type 2 diabetes patients. This study involved 9340 patients who were at high risk of CVD.

81% of participants had previously had CVD. 90% of participants had a history of high blood pressure. Although participants were prescribed multiple blood pressure-lowering drugs, only 51% of participants achieved a target blood pressure of 140/85 mmHg. Only 26% of participants achieved a target blood pressure of 130/80 mmHg.

.

The bottom line

This study concluded that blood pressure is not sufficiently controlled in the majority of T2D patients who are at high risk of CVD.

The fine print

This study included participants from various countries. The method by which measurements were sampled may have differed among countries.

What’s next?

Consult your physician regarding the options available to ensure that high blood pressure is sufficiently controlled.

Published By :

Journal of hypertension

Date :

Feb 01, 2016

Original Title :

LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.

click here to get personalized updates